Huajin Capital, based in Zhuhai, specializes in equity investment and asset management. The firm manages multiple venture capital funds, including Huajin Alpha Fund II and Huajin Alpha RMB Fund I, which focus on various sectors such as healthcare, technology, high-end equipment manufacturing, cultural media, and energy conservation. Through its investment strategies, Huajin Capital aims to support growth in these industries while also engaging in incubator activities to foster new business developments. The firm’s approach is characterized by a commitment to identifying and nurturing opportunities within China's evolving market landscape.
HighlightLL Pharma is a pharmaceutical company focused on developing drugs for immune diseases and tumors. The company is dedicated to creating innovative product lines that possess global competitive advantages. By leveraging its unique pharmacological, biological, and clinical capabilities, HighlightLL Pharma aims to provide patients with safe and affordable treatment options.
SENASIC
Series D in 2024
SENASIC is a company based in Shanghai, China, founded in 2015, specializing in the research, development, manufacture, and supply of advanced sensors and high-performance chips for automotive and industrial Internet of Things (IoT) applications. The company's primary focus is on automotive tire pressure monitoring sensors, including models that measure pressure, temperature, radial acceleration, and power supply voltage. SENASIC also develops a range of other sensors, such as MAN sensors and industrial-grade wireless temperature sensors. With a strong emphasis on low-power microcontroller technology, high-precision analog-to-digital converters, and reliable chip packaging and testing processes, SENASIC has established a reputation for producing high-quality products that meet automotive standards. Their tire pressure sensors have achieved AEC-Q10 certification, reflecting the company's commitment to enhancing vehicle safety and reliability through innovative sensor solutions.
Huali Juneng
Seed Round in 2024
Huali Juneng is a pressure vessel and related equipment producer specializing in petroleum, chemical, oil, electricity, desalination, and medical.
Bivision
Series A in 2024
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Mellow Energy
Seed Round in 2024
Mellow Energy Technology is a new calcium ore photovoltaic cell enterprise. Its business is the research and development, production and sales of centralized and distributed photovoltaic power stations.
AnDiConBio
Series A in 2024
AnDiConBio is a pharmaceutical company focused on developing drugs for respiratory anti-infection. The company has established a product pipeline that includes innovative treatments for influenza and oral medications targeting the novel coronavirus. AnDiConBio aims to deliver high-potential, low-risk products, ensuring that its offerings are both safe and effective for patients. With its commitment to addressing respiratory infections, the company seeks to provide valuable solutions in the healthcare market.
Arnatar Therapeutics
Series A in 2024
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Innovo Therapeutics
Seed Round in 2023
Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown.
Baoling Bio
Series B in 2023
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.
Huaqing Electronic Material
Series C in 2023
Huaqing Electronic Material specializes in the research, development, production, and sales of high-performance aluminum nitride ceramic substrates and electronic ceramic components. The company utilizes tape-casting manufacturing processes to create products characterized by high thermal conductivity, low dielectric constant, and excellent mechanical properties. Huaqing's offerings are primarily used in advanced fields such as 5G communications, LED packaging, power modules, image sensing, automotive electronics, aerospace, and military applications. Its products are distributed both domestically and internationally, positioning Huaqing as a leader in its industry segment.
Anmuquan Intelligent Technology
Series C in 2023
Anmuquan Intelligent Technology specializes in providing packaging solutions and software tailored for integrated circuits, particularly focusing on semiconductor components. The company aims to support the independent production of critical semiconductor elements, offering packaging services for various products, including central processing units, digital signal processors, and image processors. By enhancing the capabilities within the semiconductor industry, Anmuquan Intelligent Technology plays a vital role in promoting self-sufficiency in core component production.
OptoMedic
Debt Financing in 2023
OptoMedic specializes in the research, development, and production of advanced optical medical devices and systems. The company focuses on creating medical fluorescence navigation endoscopes that utilize aerospace and military optical technology for applications in healthcare. Its product offerings include endoscopic monitoring equipment, cancer screening tools, endoscopic navigation systems, and fluorescent imaging systems. These innovations enable medical institutions and healthcare providers to effectively observe and assess patient conditions, enhancing diagnostic capabilities and treatment outcomes.
Zhongke Hydroyi
Angel Round in 2023
Zhongke Hydroyi focuses on the research and development of polymer diaphragm products.
ECCOGENE
Series B in 2023
Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.
Singularity Energy Technology
Series B in 2023
Singularity Energy is committed to core technology research and product development in advanced energy storage systems, and contributes industry-leading solutions to promote large-scale clean energy integration and achieve global carbon neutrality goals.
Yuefang Technology
Series A in 2023
Yuefang Technology is a chip design company initiated and established by Galanz Group.
Hygea Medical
Series D in 2023
Hygea Medical Technology Co. Ltd. is a Beijing-based company that specializes in the design and manufacture of medical equipment aimed at anti-tumor treatments. The company focuses on oncology, developing solutions for cancer therapies that target diseases affecting the lung, liver, breast, and kidney. Hygea Medical is committed to advancing its micro-invasive and Cryo-HIT technology, which is utilized in cryosurgery and cryopreservation. By prioritizing research and development, Hygea Medical aims to enhance the efficiency of treatment for tumor-related diseases.
Genepoint Biological Technology
Series D in 2023
Genepoint Biological Technology (China) Co., Ltd. specializes in the manufacture of devices for cryogenic biomaterial storage and handling, aimed at supporting life sciences research. Based in Shanghai, the company offers a range of products, including Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, and LIN Vapor Freezers. These innovative solutions are designed to facilitate biotechnology research and development by enhancing the efficiency of sample storage operations. Genepoint is committed to advancing cryogenic robotic systems, enabling researchers to manage biological samples effectively and conduct experiments with greater ease.
Aiste
Venture Round in 2023
Aiste provides power conversion solutions. They offers SiC MOS chips and SiC modules for vehicles, motor drives, charging piles, wind energy inverters, photovoltaic inverters, and industrial power supplies.
Haawking
Series A in 2022
HAAWKING is a developer and manufacturer of digital signal processors and microprocessors, specializing in applications for industrial control, motor drives, digital power supplies, photovoltaic systems, energy storage, and consumer electronics. Based in China, the company emphasizes research and development in its product offerings, which also include machine vision chips tailored for use in industrial robots and intelligent applications such as augmented reality and autonomous driving. HAAWKING aims to enhance computing efficiency and reduce costs for its clients across various sectors. Customers can reach out to the company through email and phone for inquiries and support.
Vivolight
Series D in 2022
Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.
Beilai Bio
Series B in 2022
Beilai Bio is a clinical-stage biopharmaceutical company focused on the development of stem cell therapeutics for various diseases, particularly those with high unmet medical needs. Its established technology platforms allow them to produce clinical-grade "off-the-shelf" Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) from an unlimited supply of cord tissues that are traditionally regarded as medical waste.
Zhide New Energy
Series B in 2022
Zhide New Energy is a developer of approaches to synthetize new silicon anode materials. They focuses on silicon technology that can be applied to produce new materials. They also produce battery with high energy density and low cost. They manufactures battery for 3C and EV. They provide batteries for fields, such as electric vehicles, consumer electronics, house power storage, and wearable devices.
Sunwoda Electronic
Post in 2022
Sunwoda Electronic is a high-tech enterprise specializing in the research and development, design, production, and sale of lithium-ion battery cells and modules. The company offers a diverse range of products, including batteries for mobile phones, digital cameras, laptops, netbooks, electronic paper books, power-driven tools, industrial mobile lighting, and medical equipment. Sunwoda is dedicated to providing eco-friendly and efficient energy-integrated solutions, positioning itself as a key player in the battery industry.
CYGNUSEMI
Series A in 2022
Cygnus Semi is a semiconductor chip technology company that specializes in developing solutions for 5G Internet-of-Things (IoT) applications. The company focuses on creating advanced connectivity capabilities for smart devices and smart cities. Its products are designed to enhance the performance of electronic devices, allowing manufacturers to integrate high-quality chip technology into their smart products. Through its innovations, Cygnus Semi aims to support the growing demand for enhanced connectivity in various sectors.
Guizhou Core Long March Technology (Marching Power)
Series C in 2021
Guizhou Core Long March Technology, also known as Marching Power, is a high-tech company focused on the development of power semiconductor devices. Its product portfolio includes IGBT, coolmos, and SiC chip technologies, which are designed to operate under varying temperatures and voltages. The company's technical team comprises experts from the Chinese Academy of Sciences and skilled professionals from abroad, boasting substantial experience in product development. They oversee the entire process from chip design to manufacturing, packaging, testing, and reliability. Additionally, the company has a proficient marketing and operations management team well-versed in the semiconductor industry. Through its commitment to localizing power chip production, Guizhou Core Long March Technology aims to enable various enterprises to integrate high-quality semiconductors into their electronic products effectively.
Creative Technology
Venture Round in 2021
Creative Technology focuses on the surface treatment technology and product fields of wet electronic materials.
MingMed
Series A in 2021
MingMed is a Chinese pharmaceutical company focused on independent drug research and development, with a diverse product pipeline that includes ophthalmic drugs, small molecule immune drugs, and cell therapies utilizing gene editing. The company's offerings extend to recombinant protein botulinum toxin, tumor immune drugs, and immunotherapy for pets. MingMed is dedicated to producing innovative solutions across various fields, including ophthalmology, medical aesthetics, and veterinary medicine, with several of its promising drug candidates having reached the clinical stage. The company's commitment to developing First-in-Class innovative drugs positions it competitively in the global pharmaceutical market.
Gokin Solar
Angel Round in 2021
Gokin Solar specializes in the research and development, as well as the manufacturing, of high-efficiency, large-size photovoltaic silicon wafers. The company produces monocrystalline silicon rods and wafers, including sizes such as 182mm and 210mm, which are utilized in various applications, including large ground-based centralized power plants, industrial and commercial sectors, and residential photovoltaic systems. By delivering high-performance and superior-quality silicon wafers, Gokin Solar supports enterprises within the photovoltaic industry in enhancing their energy solutions.
WeRide
Series B in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Norson Biotechnology
Series B in 2020
Norson Biotechnology produces edible probiotic powder, probiotic solid beverages, fermented lactic acid bacteria beverages, and other products.
MabPlex
Series B in 2020
MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013, the company operates from its headquarters in Yantai, China, and has an additional office in Fremont, California. MabPlex provides a comprehensive range of services that encompass all stages of drug development, from DNA to finished drug products. Its offerings include customized mammalian cell medium, cell banking, and the manufacturing of monoclonal antibody active pharmaceutical ingredients, as well as fill and finish services for biologics and antibody-drug conjugates. The company aims to deliver high-quality solutions for bio-manufacturing to its global partners.
Jianghan New Materials
Series A in 2020
Jianghan New Materials is a producer of silane coupling agents, crosslinking agents, and intermediates. Their products include chlorosilane intermediate and the silane series. alkylsilane, alkoxysilane intermediate, sulfur-containing silane, ami+, phenylsilane, acyloxysilane, epoxy silane, and vinylsilane
Kingsware
Series A in 2020
Kingsware focuses on developing robotic process automation (RPA) software aimed at enhancing operational efficiency for enterprises across various sectors, including finance and supply chain. The company's RPA system automates repetitive tasks and streamlines business operations through programmed robots, allowing organizations to improve productivity and reduce manual workload. Kingsware is dedicated to creating a robust and secure robotic management platform that is user-friendly and adaptable to large-scale, integrated environments. Its solutions are designed to be safe, efficient, and stable, aligning with the demands of complex enterprise operations.
Mabwell Biotech
Series A in 2020
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
Suzhou Kintor Pharmaceuticals
Series D in 2019
Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.
Insta360
Series C in 2019
Insta360 is a technology company founded in 2014 that specializes in the development of advanced camera systems designed to help individuals capture and share their experiences. Based in Shenzhen, the company has established itself as a leader in the 360-degree camera market, offering a range of products tailored for different needs, from professional-grade models like the 8K Insta360 Pro to versatile options such as the Insta360 ONE. These cameras allow users to take high-definition 360-degree photos and videos, as well as live-stream their experiences on popular social media platforms. Insta360 also produces lightweight, portable cameras and attachments for mobile devices, catering to various scenarios including vlogging and cinematic virtual reality. The company is committed to pushing the boundaries of performance and accessibility, enabling users to create immersive content that transports viewers into new experiences.
Das Security
Venture Round in 2017
Das Security is a provider of information security technology services, offering many comprehensive solutions like application security, database security, website security monitoring, and a digital security management platform. The company maintains its corporate purpose of creating a safe and credible digital world, supports, customer success, responsibility first, open innovation, and people-oriented, common growth as the company's values, and positions itself as the security cornerstone of digitalization. It is committed to leading the global digital security industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.